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Abstract
Background:  Recent epidemiological studies have suggested that obesity is associated with
ovarian cancer. Obesity hormone leptin and its receptor (Ob-R) contribute to tumor development
by enhancing cell growth and survival. This study was design to investigate the prevalence of leptin
and Ob-R in Middle Eastern epithelial ovarian cancer (EOC) and to analyze the role of leptin and
the mechanisms under its action in EOC tissue sample and cell lines.
Methods: The expression of leptin and Ob-R was examined by immunohistochemistry in a tissue
microarray of 156 EOC samples. Proliferation of EOC cells in response to leptin was assessed by
MTT assays, and its anti-apoptotic effects were determined by flow cytometry. Effect of leptin on
PI3K/AKT signaling pathway was further determined by western blotting.
Results: In clinical samples, Ob-R overexpression was seen in 59.2% EOCs and was significantly
associated with poor progression free survival (p = 0.0032). Furthermore, Ob-R expression was
associated with anti apoptotic proteins Bcl-XL (p = 0.0035) and XIAP (p = 0.0001). In vitro analysis
using EOC cell lines showed that leptin stimulated cell proliferation and inhibits apoptosis via
activation of PI3K/AKT signaling pathway. Inhibition of PI3K activity by LY294002, a specific
inhibitor of PI3-kinase abrogated leptin mediated PI3K/AKT signaling. Gene silencing of Ob-R with
Ob-R siRNA in EOC cells resulted in down regulation of phospho-AKT and its down stream
targets.
Conclusion:  Our findings have potential clinical implication for EOC development and
progression.
Background
Despite rapid advances in understanding ovarian cancer
etiology, epithelial ovarian cancer (EOC) remains the
most lethal form of gynecologic cancers [1-4]. Malignant
transformation of normal ovarian epithelial cells is caused
by genetic alteration that disrupts proliferation, pro-
grammed cell death and senescence.
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Leptin, the product of obesity gene (Ob) is suggested to be
associated with cancer development and progression in
many epithelial cancers including EOC [5-8]
Leptin is 16KD adipokine produced predominantly by
adipocytes with wide range of biological activities includ-
ing appetite regulation, bone formation, reproductive
function and angiogenesis [9-11]. Leptin mediated signal-
ing pathways play an important role in cancer cell prolif-
eration, invasion and metastasis [5]. Leptin exerts its
activity through specific membrane receptor, the obesity
receptor (Ob-R), which is assigned to class I cytokine
receptor family [12]. Six splice variants of Ob-R have been
identified up to now; a long isoform, four short isoforms
discriminated by the different lengths of intracellular
domain, and the secreted isoform, which modulates
blood leptin [12,13]. According to the current knowledge,
leptin signaling pathway is mainly transduced by JAK/
STAT, MAPK and PI3K signaling pathways [5]. Previous
study [8] has suggested that leptin signaling pathway is
transmitted via MAP kinase pathway. However, the inter-
action between leptin signaling and PI3K/AKT pathway in
ovarian cancer remains unknown.
A recent epidemiological study [14] has found that among
women who have never used menopausal hormone ther-
apy, obese women are at increased risk of developing
ovarian cancer compared with women of normal weight.
Although a hormonal mechanism was suggested as a link
between ovarian cancer and obesity, at present, a clear
biological explanation for risk associated between obesity
and EOC is not fully known. Therefore, the effects of obes-
ity on ovarian cancer represent a critical intersection
between these two important health problems. However,
whether there is a direct relationship between leptin and
ovarian cancer cannot be conclusively stated as increased
leptin and ovarian cancer may both be secondary conse-
quences of obesity. Considering the fundamental role of
leptin and Ob-R in cancer development and progression,
we sought to examine the expression pattern of leptin and
Ob-R in large cohort of Middle Eastern EOC using TMA
immunohistochemical analysis. We then examined the
expression of leptin and Ob-R using EOC cell lines. Fur-
thermore, we investigated the effect of leptin on malig-
nant properties of EOC including proliferation and
apoptosis. Finally we elucidated the PI3K/AKT signal
transduction pathway regulating leptin-induced changes
in the cancerous properties of EOC.
Results
Immunohistochemical detection of Ob-R expression and 
its association with clinicopathological parameters
Ob-R expression was seen in 59.2% (90/152) of the EOCs
analyzed (Figure 1). No association was observed between
Ob-R overexpression and age, FIGO Stage, Histology type
and grade (Table 1). Ob-R expression was linked to PI3K/
AKT signaling pathway as evidenced by direct association
of Ob-R expression with pGSK3 (p = 0.0009), PTEN (p =
0.0002) and end stream anti-apoptotic markers XIAP (p =
0.0001) and Bcl-XL (p = 0.0035) expression. However no
association was seen with p-AKT (p = 0.2082).
Ob-R expression and progression overall survival
EOC patients with low expression of Ob-R had a poor
progression free survival (PFS) of 13.1 months as com-
pared to 21 months (p = 0.0032) with low Ob-R expres-
sion (Figure 2). In the multivariate analysis using Cox
Proportional Hazard model for multiple factors like age,
FIGO stage, grade and Ob-R expression, the relative risk
was 1.96 for high Ob-R expression (95% CI 1.28-3.06; p
= 0.0020) and 1.81 for AJCC stage IV (95% CI 1.08-2.93;
p = 0.0243). Thus Ob-R overexpression was an independ-
ent prognostic marker for poor survival in multivariate
analysis (Table 2).
Immunohistochemical detection of leptin expression and 
its association with clinicopathological parameters
Leptin expression was noted in 89.5% (128/143) of the
EOCs analyzed and leptin staining was seen in the nuclear
as well as cytoplasmic compartment. As shown in Table 3
leptin expression was linked to PI3K/AKT signaling path-
way as evidenced by direct significant association of leptin
expression with p-AKT (p = 0.0344). However no associa-
tion was seen with expression of PTEN (p = 0.3096) and
end stream anti-apoptotic markers XIAP (p = 0.3500) and
Bcl-XL (p = 0.1724). Also leptin overexpression was not
associated with patient's age, histology type, tumor grade,
FIGO stage and progression free survival (Table 3).
Leptin increase proliferation of EOC cells
The effects of leptin on growth rate of EOC cell lines were
determined using MTT assay. MDAH2774 and SKOV3
cells were initially serum starved for 24 hours and then
stimulated with various doses of recombinant leptin (10-
200 ng/ml) for 48 hours compared to with cell serum free
control cultures. As shown in Figure 3A, leptin induced
significant cell growth of both EOC cell lines in a dose
dependent manner.
Leptin prevent serum-starved apoptosis in EOC cells
EOC cell lines were seeded in six well plates and after 24
hours serum free medium alone or 100 ng/ml leptin was
added. After 48 hours, apoptosis was measured by
annexin/PI staining. As shown in Figure 3B, serum starva-
tion resulted in apoptosis. Treatment of EOC cell line with
leptin significantly prevented serum starved apoptosis
suggesting that leptin counteract apoptosis in EOC cells (p
= 0.0005).Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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Leptin activates the PI3-Kinase/AKTsignaling pathway
PI3-kinase/AKT pathways have been implicated in playing
crucial roles in regulating cell growth, cell proliferation
prevention of apoptosis, which altogether attribute tum-
origenesis [15]. In view of these findings we sought to
determine whether PI3-kinase signaling is activated dur-
ing leptin stimulated EOC cell line proliferation.
MDAH2774 cells were stimulated with 100 ng/ml leptin
for various time periods. Cells were lysed and proteins
were separated on SDS-PAGE and immunoblotted with p-
AKT (activated AKT) and p-FOXO1 antibodies. As shown
in Figure 4A, leptin treatment of MDAH2774 phosphor-
ylated AKT and FOXO1 as early as 15 minutes and
remained phosphorylated till 3 hours. Similar results were
Table 1: Correlation between Leptin-R(Ob-R) Status and clinical status in Epithelial Ovarian Carcinoma (EOC).
Epithelial Group Leptin-R high Leptin-R low P value
N% N % N %
Total Number of Cases 152 90 59.2 62 40.8
Age
< = 50 years 59 38.8 34 57.6 25 42.4 0.7519
>50 years 93 61.2 56 60.2 37 39.8
Tumour Stage
Stage I-II 8 5.6 5 62.5 3 37.5 0.8749
Stage III-IV 134 94.4 80 59.7 54 40.3
Histopathology
Clear cell 4 2.6 3 75.0 1 25.0 0.2909
Endometriod 21 13.8 13 61.9 8 38.1
Serous 122 80.3 73 59.8 49 40.2
Undifferentiated 5 3.3 1 20.0 4 80.0
FIGO Grade
Well differentiated 27 17.8 15 55.6 12 44.4 0.9031
Moderately Diff 81 53.3 49 60.5 32 39.5
Poorly Diff 44 29.0 26 59.1 18 40.9
P-AKT Ser 473
High (2-3) 75 52.1 49 65.3 26 34.7 0.2082
Low (0-1) 69 47.9 38 55.1 31 44.9
pGSK3B(Ser9)
Above 45 116 81.7 77 66.4 39 33.6 0.0009
Below = 45 26 18.3 8 30.8 18 69.2
PTEN
0-1 33 22.9 11 33.3 22 66.7 0.0002
2-3 111 77.1 77 69.4 34 30.6
XIAP
Above 70 128 88.3 84 65.6 44 34.4 0.0001
Below = 70 17 11.7 3 17.6 14 82.4
Bcl-XL
Above 180 122 85.9 79 64.7 43 35.3 0.0035
Below = 180 20 14.1 6 30.0 14 70.0
PFS Median (Months)^ 13.1 21.0 0.0032
#of the 152 EOCs with available Ob-R expression data, FIGO stage was available only in 142 cases; in remaining stage was unknown.
$ Analysis failure of some markers for these IHC markers was attributed to missing or non representative spots
^PFS= progression free survivalMolecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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Tissue microarray based immunohistochemical analysis of Ob-R, pGSK3, Bcl-XL and XIAP in EOC patients Figure 1
Tissue microarray based immunohistochemical analysis of Ob-R, pGSK3, Bcl-XL and XIAP in EOC patients. 
An EOC tissue microarray spot showing over expression of (a) Ob-R, (b) pGSK3, (c) Bcl-XL and (d) XIAP. In contrast, another 
EOC tissue microarray spot showing low expression of (e) Ob-R, (f) pGSK3, (g) Bcl-XL and (h) XIAP. 20 X/0.70 objectives on 
an Olympus BX 51 microscope (Olympus America Inc, Center Valley, PA, USA. With the inset showing a 40X/0.85 aperture 
magnified view of the same.Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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obtained with other EOC cell lines (data not shown).
These results suggest that leptin mediated cell prolifera-
tion occurs via PI3K/AKT signaling pathway.
Inhibition of PI3-kinase prevents leptin mediated AKT 
activation and its downstream effector FOXO1
Since our study suggesting that leptin stimulated PI3-
kinase signaling plays a role in EOC proliferation and pro-
motes its anti-apoptotic effects. We sought to determine
whether the inhibition of PI3'-kinase by its specific inhib-
itor, LY294002, abrogated leptin mediated PI3K/AKT sig-
naling in EOC cell lines. Cells were seeded on culture
plates for 24 hours. Starved EOC cell were pre-treated with
20 μM LY294002 for 2 hours and subsequently treated
with and without 100 ng/ml leptin for 3 hours. Cells were
lysed and proteins were separated on SDS-PAGE and
immunoblotted by antibodies against p-AKT and p-
FOXO1. As shown in Figure 4B, leptin phosphorylated
AKT and FOXO1 in MDAH2774 cell line and pre-treat-
ment with LY294002, prevented AKT and FOXO1 phos-
phorylation. In addition, pre-treatment of EOC cells with
LY294002, abrogated leptin-induced cell proliferation
(Figure 4C) as well as prevented leptin-mediated anti-
apoptotic effects (Figure 4D) on EOC cells suggesting that
PI3-kinase/AKT pathway plays a critical role in leptin-
induced growth and proliferation of EOC cells. These data
is also suggesting that leptin is acting upstream of PI3-
kinase/AKT pathway in modulating its anti-apoptotic
response in EOC cells.
EOC cell lines express leptin receptors that mediate the 
PI3-kinase/AKT signaling pathways
To investigate whether leptin receptors are functional and
linked to coordinate with PI3-kinase/AKT signaling path-
way to regulate cell growth and proliferation of EOC cell
lines, we utilized small interfering RNA (siRNA) strategies
to transfect Ob-R specific siRNA as well as scrambled non
specific siRNA in MDAH2774 cell line. After 48 hours
transfection, cell were starved and then treated with and
without 100 ng/ml leptin for 3 hours. As shown in Figure
5, MDAH2774 expressed functional leptin receptors, as
shown previously[4] Treatment of scrambled siRNA har-
boring MDAH2774 cells with leptin showed activation of
AKT, FOXO1 and elevated level of XIAP and Bcl-XL pro-
teins that are involved in PI3-kinase/AKT pathway and
play a critical role in cell survival. On the other hand
expression of Ob-R specific siRNA in MDAH2774 cells
knocked down the expression of Ob-R and prevented lep-
tin-induced activation of AKT, FOXO1 as well as abro-
gated the expression of XIAP and Bcl-XL proteins. These
data suggests that leptin utilizes PI3-kinase/AKT signal
transduction pathway in mediation of EOC cell prolifera-
tion, further confirming that leptin is acting upstream of
PI3K/AKT pathway.
Discussion
Recent reports suggest that leptin is overexpressed in vari-
ous cancer cells and plays a role in the development and/
Table 2: Univariate and Multivariate analysis of Ob-R in Epithelial Ovarian Cancer using Cox Proportional Hazard Model.
Clinical Parameters UNIVARIATE MULTIVARIATE
Risk Ratio (95% CI) P value Risk Ratio (95% CI) P value
Age
Above = 50
0.80 (0.54-1.19) 0.2751 0.74 (0.49 - 1.14) 0.1712
Stage
IV
2.15 (1.32 - 3.41) 0.0028 1.82 (1.08 - 2.93) 0.0243
Grade
Poor
1.27 (0.82-1.93) 0.5303 1.15 (0.72 - 1.79) 0.5445
Leptin R(Ob-R)
Overexpression
1.82 (1.22-2.75) 0.0032 1.96 (1.28 - 3.06) 0.0020
CI: Confidence Interval
Kaplan Meier survival analysis in EOC patients showing  reduced or absent leptin-R (n = 52) and those with high  expression of Ob-R (n = 68) Figure 2
Kaplan Meier survival analysis in EOC patients show-
ing reduced or absent leptin-R (n = 52) and those 
with high expression of Ob-R (n = 68).Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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or progression of variety of variety of malignancies includ-
ing colon, gastric, endometrial and breast cancers [16-20].
These findings were further supported by experimental
evidence that leptin can stimulate growth and prevent
apoptosis in different cellular cancer models [21-23]. A
very recent epidemiological study has shown that obesity
is a risk factor for ovarian cancer in postmenopausal
women [14]. High levels of serum estrogen, derived from
increased adipose tissue are considered to contribute to
the pathogenesis of ovarian cancer in those obese
patients. However, circulating leptin is an essential factor
regulating fat metabolism, it can be hypothesized that lep-
tin itself might be involved in the development of ovarian
cancer.
Table 3: Correlation between leptin Status and clinical status in Epithelial Ovarian Carcinoma (EOC).
Epithelial Group Leptin High Leptin low p value
N% N %N %
Total Number of Cases 143 128 89.5 15 10.5
Age
< = 50 years 57 39.9 53 93.0 4 7.0 0.2588
>50 years 86 60.1 75 87.2 11 12.8
Tumour Stage
Stage I-II 8 6.0 7 87.5 1 12.5 0.9115
Stage III-IV 125 94.0 111 88.8 14 11.2
Histopathology
Clear cell 4 2.8 3 75.0 1 25.0 0.6630
Endometriod 21 14.7 19 90.5 2 9.5
Serous 114 79.7 102 89.5 12 10.5
Undifferentiated 4 2.8 4 100.0 0 0
FIGO Grade
Well differentiated 27 18.9 24 88.9 3 11.1 0.9815
Moderately Diff 75 52.5 67 89.3 8 10.7
Poorly Diff 41 28.7 37 90.2 4 9.8
P-AKT Ser 473
High (2-3) 74 52.1 70 94.6 4 5.4 0.0344
Low (0-1) 68 47.9 57 83.8 11 16.2
pGSK3B(Ser9)
Above 45 116 81.7 103 88.8 13 11.2 0.5852
Below = 45 26 18.3 24 92.3 2 7.7
PTEN
Low (0-1) 32 22.5 27 84.4 5 15.6 0.3096
High (2-3) 110 77.5 100 90.9 10 9.1
XIAP
Above 70 124 87.9 112 90.3 12 9.7 0.3500
Below = 70 17 12.1 14 82.3 3 17.7
Bcl-XL
Above 180 122 85.9 111 91.0 11 9.0 0.1724
Below = 180 20 14.1 16 80.0 4 20.0
PFS Median (Months)^ 17.0 10.3 0.1422
# of the 143 EOCs with available Ob-R expression data, FIGO stage was available only in 133 cases; in remaining stage was unknown.
$ Analysis failure of some markers for these IHC markers was attributed to missing or non representative spots
^PFS= progression free survival Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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Therefore, we first examined the prevalence of leptin and
its receptor Ob-R expression in 156 Saudi EOC samples.
Our data shows that Ob-R protein was detected in 59.2%
examined EOCs. Interestingly, patients with high Ob-R
expression tumors showed a significant poor disease free
survival (p = 0.0032) compared with reduced Ob-R
expression which support the proposed role of leptin sig-
naling in the EOC. Furthermore, Ob-R overexpression was
an independent prognostic variable to predict poor pro-
gression free survival. Interaction between leptin/Ob-R
and other signaling pathways such as PI3K/AKT and MAP
kinase have been reported in oncogenesis of various
tumors [5,8,22,24-26]. Therefore, we examined the rela-
tionship between the expression of Ob-R and the PI3K/
AKT pathway protein targets in EOC. Activated AKT pro-
tein expression was seen in 52% of our EOC examined.
However, no correlation was observed with Ob-R expres-
sion and AKT activation by IHC staining which might sug-
Leptin increase proliferation of EOC cells and prevents serum starved apoptosis in EOC cells Figure 3
Leptin increase proliferation of EOC cells and prevents serum starved apoptosis in EOC cells. (A) SKOV3 and 
MDAH2774 cell lines were seeded in 96 well plates and after 24 hours serum free medium alone or with various doses of lep-
tin as indicated was added. After 48 hours cell proliferation was measured MTT as described in materials and methods. The 
graph displays the mean +/-SD (standard deviation) of six independent experiments. (B) EOC cell lines were seeded in six well 
plates and after 24 hours serum free medium alone or 100 ng/ml was added. After 48 hours apoptosis was measured by 
annexin/PI staining.Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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gest the presence of other upstream signaling pathways
can also be involved in the activation of AKT. However
Ob-R overexpression was correlated with pGSK3 expres-
sion (p = 0.0009), PTEN (p = 0.0002) and other down-
stream targets of PI3K/AKT, the anti apoptotic markers
Bcl-XL and XIAP (p = 0.0035 and p = 0.0001 respectively).
In addition leptin expression was seen in 89.5 of the EOCs
was linked to PI3K/AKT signaling pathway as evidenced
by direct significant association of leptin expression with
p-AKT. However leptin expression was not associated with
any clinicopathological parameters including progression
free survival. BMI data was available in 100 patients and
no association was noted between leptin expression by
IHC and BMI. (p = 0.1260; data not shown). Thus we can
hypothesize that intratumoral intracellular leptin unlike
Leptin activate PI3-kinase/AKT signaling pathway Figure 4
Leptin activate PI3-kinase/AKT signaling pathway. (A) MDAH2774 cells were serum starved for 24 hours in serum free 
medium, followed by stimulation with recombinant leptin (100 ng/ml) for various time periods as indicated. After cell lysis, 20 
μg proteins were separated by SDS-PAGE, transferred to immobilon membrane, and immunoblotted with antibodies against p-
AKT-Ser 473, FOXO1, and beta actin. (B) Inhibition of PI3-kinase/AKT pathway prevented leptin-induced activation of AKT 
pathway in EOC cells. SKOV3 cells were serum starved in the presence and absence of LY294002 as indicated for 48 hours 
and subsequently stimulated with 100 ng/ml of recombinant leptin for 3 hours, Cells were lysed and proteins were separated 
by SDS-PAGE, transferred to immobilon membrane, and immunoblotted with antibodies against p-AKT-Ser 473, FOXO1, and 
beta actin. (C) LY294002-inhibitor abrogate leptin-mediated cell proliferation and prevented leptin-induced anti-apoptotic 
effects in EOC cells. MADH2774 and SKOV3 cells were serum starved in the presence and absence of LY294002 as indicated 
and subsequently stimulated with 100 ng/ml of recombinant leptin for 48 hours. Cell proliferation was measured by MTT assays 
and (D) apoptosis was measured by Anenexin/PI staining. The graph displays the mean +/- SD of six independent experiments 
(* p < 0.05).Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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serum leptin levels are not associated with body mass
index
Furthermore, in vitro analysis using EOC cell lines was
conducted to study the affect of leptin on EOC cell
growth. Our experiments clearly showed that leptin has
oncogenic affect on EOC cells and this oncogenic effect is
due to a combination of cell proliferation and inhibition
of apoptosis by leptin. To elucidate the signaling path-
ways involved in leptin mediated induction of cancerous
properties of EOC cells, we examined the effect of leptin
in activation of the PI3K/AKT pathway. Our data showed
that leptin rapidly stimulates the PI3K/AKT pathway and
induced phosphorylation of AKT thus activating this key
signal transduction pathway associated with cell growth.
In addition, prevention of leptin-induced activation of
PI3K/AKT with pharmacological inhibition in turn signif-
icantly reduced the activation of AKT. In addition our data
showed that gene silencing of Ob-R in EOC cell lines
abrogated the AKT activation as well as the expression of
anti-apoptotic genes, XIAP and Bcl-XL suggesting that lep-
tin mediated EOC growth is due to modulation of growth
and anti-apoptotic genes.
Conclusion
Our data suggests that leptin pathway might play a major
role in Middle Eastern EOC, and deciphered the molecu-
lar mechanisms responsible for leptin mediated EOC cell
proliferation, establishing direct association between
obesity and EOC carcinogenesis and presenting involve-
ment of key molecules of oncogenic PI3K signaling path-
way.
Methods
Patient selection
156 patients with ovarian carcinoma diagnosed between
1991 to 2007 were selected from the files of the King
Faisal Specialist Hospital and Research Centre. All sam-
ples were analyzed in a tissue microarray (TMA) format.
The Institutional Review Board of the King Faisal Special-
ist Hospital & Research Centre approved the study.
The patients included in this study had their diagnosis,
treatment and follow-up care in the departments of
Obstetrics and Gynecology and Oncology at King Faisal
Specialist Hospital and Research Centre. The histological
subtype of each ovarian tumor sample was determined
according to established criteria [27], the distribution of
tumors by histological type was as follows: 125 serous
(80.1%), 22 endometrioid (14.1%), 4 clear cell (2.6%)
and 5 undifferentiated/mixed Epithelial (3.2%). The
median age of the patient population was 56 years with a
range from 19-86 years. The majority of patients under-
went primary surgical staging or cytoreduction. In some
patients who were not fit for primary surgery, primary
neoadjuvant chemotherapy was followed by interval
debulking surgery. The distribution by FIGO stage at diag-
nosis was: stage I-II in 8 patients (5.1%), stage III-IV in
137 (87.8%), and unknown in 11(7.1%). The median fol-
low-up time was 14.9 months (range, 1-130 months).
Progression free survival was computed from date of sur-
gery for patients who underwent primary cytoreduction
and from date of diagnosis by biopsy or cytology in those
who underwent primary neoadjuvant chemotherapy.
Since the majority of patients are lost to follow-up as their
disease reaches its terminal stages, it was impossible to
determine overall survival in this specific patient popula-
tion.
Tissue Microarray (TMA) Construction
Tissue microarrays were constructed from formalin-fixed,
paraffin-embedded ovarian cancer specimens as described
previously [28]. Tumor regions were mapped by a pathol-
ogist for coring. The tissue microarray was constructed
with 0.6-mm diameter cores spaced 0.8 mm apart using a
modified Tissue Microarrayer (Beecher Instruments, Sun
Prairie, WI, USA). The tissue microarray block was cut into
5 mm sections, adhered to the slide by an adhesive tape-
Leptin required functional leptin receptor (Ob-R) for activa- tion of PI3-kinase/AKT signaling in EOC cell lines Figure 5
Leptin required functional leptin receptor (Ob-R) for 
activation of PI3-kinase/AKT signaling in EOC cell 
lines. MDAH2774 cells were transfected with scrambled 
siRNA and Ob-R siRNA (50 and 100 nM) with Lipo-
fectamine. After 48 hours, cells were starved and treated 
with 100 ng/ml for 3 hours and proteins were immuno-blot-
ted with antibodies against Ob-R, p-AKT-Ser473, and 
FOXO1, Bcl-XL, XIAP and beta actin.Molecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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transfer method (Instrumedics Inc., Hackensack, NJ, USA)
and UV cross linked.
Antibodies and immunohistochemistry
Immunohistochemical studies on formalin-fixed, paraf-
fin-embedded tissue sections were performed as describer
in earlier studies [28,29]. Primary antibodies used, their
dilutions, and other information is listed in Table 4. For
antigen retrieval, Dako Target Retrieval Solution pH 6.0
(Catalogue number S1700) was used, and the slides were
microwaved at 750W for 5 minutes and then at 250W for
30 minutes. The sections were incubated overnight with
Ob-R) and the Dako Envision Plus System kit was used as
the secondary detection system with DAB as chromogen.
We used a mouse monoclonal antibody from Santa Cruz
Biotechnology; Clone B3 to detect Ob-R expression and
this antibody binds to both short and long forms of Ob-
R. Similarly, leptin expression was detected by using a rab-
bit monoclonal antibody Y20 from from Santa Cruz Bio-
technology. IHC for p-AKT was performed by staining 3-4
micrometer thick tissue micro array sections with the p-
AKT (Ser 473) antibody [Survival Marker: Signal Stain
Phospho-AKT (Ser 473) IHC detection kit Product No
8100 Cell Signaling Technology, Beverly, MA]. The IHC
protocol included with the kit was followed with no mod-
ifications. Incubating the tissue in blocking solution
blocked nonspecific binding. Endogenous peroxidase
activity was quenched using peroxidase quench supplied
along with the kit. Endogenous biotin was blocked and all
slides were counterstained with hematoxylin, dehydrated,
cleared, and cover slipped with premount. Only fresh cut
TMA slides were stained simultaneously to minimize the
influence of slide aging and maximize repeatability and
reproducibility of the experiment. Two types of negative
controls were used. One was the negative control in the kit
in which the primary antibody was omitted. A preabsorp-
tion experiment using p-AKT Ser 473 blocking peptide
(Cell Signaling Technology, Beverly, MA, Product No
1140) was used as the second negative control
Immunohistochemistry Assessment
In this study, Ob-R expression was categorized by doing
an H score, which combines intensity of staining in each
cell and percentage of stained cells. In brief, each TMA
spot was assigned a staining intensity score from 0-3 [I0,
I1-3], and a percent of stained tumor cells that was
recorded in 5% increments from a range of 0-100 (P0, P1-
3). For each spot analyzed, a score was generated from the
product of intensity and percent of tumor cells stained. A
final H score (range 0-300) was obtained by adding the
sum of individual scores obtained for each tissue microar-
ray spot. (H score = I1XP1+I2XP2+I3XP3). Ovarian
tumors were categorized into 2 groups based on H score
and using the X-tile plat as described below.
X-tile plots are constructed for assessment of biomarker
and optimization of cut off points based on outcome
[30,31]. The X-Tile plots allow determination of an opti-
mal cut point while correcting for the use of minimum P
statistics. Using the X-Tile program, an optimal cut point
for Ob-R expression was determined at 20, with a Miller-
Seigmund p value of 0.5950 as determined by X-Tile.
Tumors with H score <20 were classified as low expressers
(n = 62; 40.8%), and those with H score >20 were classi-
fied as high expressers (n = 90; 59.2%; Figure 1a and 1e).
Similarly X-Tile was used to determine a cut point for lep-
tin, Bcl-XL, XIAP, PTEN and pGSK3.
p-AKT & PTEN scoring was done as described earlier
[32,33]. Briefly, p-AKT was scored as levels on an intensity
scale ranging from 0 to 3. Scoring was performed as fol-
lows: 0, no appreciable staining in tumor cells; 1, barely
detectable staining in tumor cells; 2, appreciable staining
of moderate intensity, distinctly marking tumor cells and
Table 4: Antibodies used for tissue micro array Immunohistochemical analysis.
Antibody Clone Company Source Dilution
O/N@
Retrieval Sub cellular 
Localization
Detection 
System
Leptin-R B-3 SCBT Mouse monoclonal 1:20 O/N pH9, Pressure 
cooker
Cytoplasmic EnVision+
Leptin Y20 SCBT Rabbit monoclonal 1:1000 O/N pH6, Pressure 
cooker
Nuclear & 
Cytoplasmic
EnVision+
PTEN 6H2-1 Cascade Bioscience Mouse monoclonal 1:100 pH9, Pressure 
cooker
Cytoplasmic EnVision+
pAKT Ser473 Cell Signalling Rabbit polyclonal Predilute O/N pH9, Microwave Nuclear & 
Cytoplasmic
Survival Marker; 
signal stain IHC 
detection kit
XIAP 48 BD Transduction Mouse monoclonal 1:300 O/N pH9, Microwave Cytoplasmic EnVision+
BCLXL 54H6 Cell Signalling Rabbit polyclonal 1:800 O/N pH9, Microwave Cytoplasmic EnVision+
pGSK3 Ser21/9 Cell Signalling Rabbit polyclonal 1:50 O/N pH9, Pressure 
cooker
Cytoplasmic EnVision+
@overnight incubation of primary antibodyMolecular Cancer 2009, 8:74 http://www.molecular-cancer.com/content/8/1/74
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3, readily appreciable staining of strong intensity. For pur-
poses of statistical analysis, all cases staining at level 0 or
1 were grouped as p-AKT negative and all cases staining at
level 2 and level 3 were grouped as p-AKT positive.
Statistical Analysis
The JMP7 (SAS Institute, Inc., Cary, NC) software package
was used for data analyses. Survival curves were generated
using the Kaplan-Meier method, with significance evalu-
ated using the Mantel-Cox log-rank test. Risk ratio was cal-
culated using the Cox Proportional Hazard model in both
univariate and multivariate analyses. Chi-square tests
were used to examine relationship between nominal vari-
ables. The limit of significance for all analyses was defined
as a p-value of 0.05.
Cell culture
Ovarian cancer cell line, were used: MDAH2774 and
SKOV3 cells were cultured in RPMI 1640 medium supple-
mented with 10% (vol/vol) fetal bovine serum (FBS), 100
U/ml Penicillin and 100 U/ml Streptomycin at 37°C in
humidified atmosphere containing 5% CO2. All experi-
ments were performed in RPMI 1640 containing 5%
serum.
Reagents and antibodies
Leptin and 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphe-
nyltetrazolium Bromide (MTT) assays were purchased
from Sigma (St. Louis MO, MA). Ob-R antibody was pur-
chased from Abcam (Cambridge, United Kingdom). Anti-
bodies against phospho-AKT, phospho-FKHR/FoxO1
antibodies were purchased from Cell Signaling Technolo-
gies (Beverly, MA, USA). Beta-actin antibody was pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Annexin V kit was purchased from Molecular
Probes (Eugene OR, USA). Apoptotic DNA-ladder kit was
obtained from Roche (Penzberg, Germany).
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium 
Bromide Assays
104 cells were incubated in triplicate in a 96-well plate in
the presence or absence of indicated test doses of leptin in
a final volume of 0.20 ml for 48 hour. The ability of leptin
to induce cell growth was determined by MTT cell prolif-
eration assays, as previously described [34]. Replicates of
6 wells for each dosage including vehicle control were
analyzed for each experiment.
Annexin V/Propidium Iodide Dual Staining
EOC cell lines were treated with the indicated concentra-
tions of leptin in conditions treated as indicated in Figure
legends. The cells were harvested and the percentage of
cells undergoing apoptosis was measured by flow cytom-
etry after staining with fluorescein-conjugated AnnexinV/
propidium iodide as previously described [35].
Cell lysis and Immunoblotting
Cells were treated either with leptin or leptin in combina-
tion with PI3-kinase inhibitor LY294002 described in the
legends and lysed as previously described [36]. Proteins
(15-20 μg) were separated by SDS-PAGE and transferred
to polyvinylidene difluoride (PVDF) membrane (Immo-
bilon, Millipore, Billerica, MA). Immunoblotting was
done with different antibodies and visualized by the
enhanced chemiluminescence (Amersham, Piscataway,
NJ) method.
Gene silencing using small interfering RNA (siRNA)
Leptin receptor siRNA and scrambled control siRNA were
purchased from Qiagen (Valencia, CA, USA). Cells were
transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) and siRNA as described earlier [37]. After
transfection for 6 hours, the lipid and siRNA complex was
removed and fresh growth medium was added and incu-
bated for 48 hours. Cells were then treated with leptin as
indicated and after lysis protein levels were determined by
Western Blot analysis with specific antibodies.
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